Egg Hydrolytic Enzyme Veterinary Grade API is a purified peptidoglycan N-acetylmuramoylhydrolase (EC 3.2.1.17; CAS 12650-88-3) obtained from hen egg white and standardised for veterinary pharmaceutical processing into tablets, injections, capsules, powders, granules, premix, and oral solutions. The enzyme consists of a single polypeptide chain of approximately 129 amino acid residues with a molecular mass of 14.3 kDa and an isoelectric point near 11. It catalyses hydrolysis of the β-1,4-glycosidic linkage between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in bacterial peptidoglycan, a mechanism that does not target host cell membranes. Manufacturer release codes for veterinary-grade material typically incorporate dosage-form compatibility and assay tier: EHE-VG/DT for direct-tablet powder, EHE-VG/INJ for low-endotoxin lyophilised injection powder, EHE-VG/PRM for granular premix, and EHE-VG/SOL for drinking water or solution formulations. The code suffix is not a pharmacopoeial descriptor but a supplier-specific model identifier that is mapped to the batch certificate of analysis.

Specification differentiation begins with route of administration. Oral tablet, capsule, and powder grades are released with a minimum activity of 20,000 FIP units/mg on the dried substance, loss on drying no greater than 5.0%, and total aerobic microbial count no greater than 10^3 CFU/g. Parenteral solution grade is manufactured from the same active substance but is additionally processed through chromatographic purification and aseptic lyophilisation to achieve a bacterial endotoxin limit of 0.05 EU/mg by Ph. Eur. 2.6.14, a loss on drying no greater than 2.0%, and total aerobic microbial count no greater than 10^1 CFU/g by Ph. Eur. 2.6.12. Residual moisture is controlled because water uptake above the specified limit reduces chemical stability and interferes with dry powder flow and tablet hardness.

Which Release Tests Are Applied Differently to Oral and Parenteral Veterinary Grades?

Release activity is expressed in FIP units per milligram against a Micrococcus lysodeikticus reference substrate under the turbidimetric method cited in compendial lysozyme monographs. The following table summarises the representative veterinary release specification across dosage-form grades.

Identification is performed by peptide mapping against the reference standard and by an enzymatic activity overlay. Identity alone is not sufficient for veterinary API release; the batch certificate also includes residual protein profile, host allergen limits, and stability data generated under conditions appropriate to the dosage form. The presence of unhydrolysed egg protein species is controlled because residual ovalbumin and ovomucoid are relevant to hypersensitivity risk in target animals.

Veterinary formulations containing egg hydrolytic enzyme are administered orally as tablets, capsules, powders, granules, premixes, or solutions where enzymatic cleavage of bacterial peptidoglycan is intended to reduce Gram-positive bacterial load on mucosal surfaces or in the gastrointestinal tract. The enzyme is not absorbed systemically to a significant extent and does not act on Gram-negative organisms unless the outer membrane has been permeabilised; this narrow spectrum is a critical difference from broad-spectrum antimicrobial drugs and reduces selection pressure for plasmid-mediated resistance genes. Published field efficacy data for this specific configuration are limited, and product indications must be evaluated against the target species and the registered veterinary medicinal product dossier.

Compression Behavior of Direct-Tablet Veterinary Grade API

Direct-compression tablet formulations require particle size, bulk density, and moisture control because the enzyme has limited intrinsic compaction capacity unless preconditioned. The direct-tablet grade is blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and sodium stearyl fumarate in a bin blender for 15–20 min at 60–70% fill volume. The blend is compressed on a rotary tablet press equipped with precompression rolls and a main compression force window of 15–25 kN; tablet hardness is maintained at 50–80 N, friability is below 1.0% after 100 revolutions by Ph. Eur. 2.9.7, and disintegration is under 15 min in water at 37°C by Ph. Eur. 2.9.1. Direct-compression formulations above 50 mg active per tablet tend to cap unless the API is dry-granulated by roller compaction at a gap of 1.0–1.5 mm and a roll pressure of 60–80 bar. Published data for direct-compression loading above 100 mg in large veterinary boluses is limited.

Capsule filling on dosator-type machines requires control of particle-size span and flow. The oral powder grade conditioned to a bulk density of 0.35–0.55 g/mL and tapped density of 0.55–0.75 g/mL produces fill-weight variability below 5% relative standard deviation when the D10 exceeds 20 µm and the D90 remains below 150 µm. Granular premix and powder formulations are buffered with sodium acetate to pH 4.0–5.0; solution preparations maintain activity above 95% for 24 h at 25°C under these conditions, while unpurified egg protein hydrolysates exhibit precipitation and variable enzymatic recovery in the same matrix.

When the Injection Grade Is Specified for Aseptic Filling Lines

For parenteral solutions, the lyophilised API is dissolved in water for injection at 10–20 mg/mL, and the solution is clarified through 0.22 µm polyethersulfone sterilising-grade filters before aseptic filling. Adsorption of the enzyme to container-closure elastomers at low protein concentration is mitigated by inclusion of 0.05% polysorbate 80 and 0.9% sodium chloride. Terminal steam sterilisation is not recommended because activity loss of 30–40% is observed after 121°C for 15 min; aseptic filtration is therefore the standard manufacturing route. The parenteral grade is controlled for subvisible particulate matter by Ph. Eur. 2.9.19 and for bacterial endotoxin as described. SDS-PAGE purity is not less than 95%, and residual ovalbumin is held below 0.1% w/w by ELISA; this threshold reduces but does not eliminate type I hypersensitivity risk in target species.

Compared with unstandardised egg protein hydrolysates sold as feed or food ingredients, the veterinary-grade API is not interchangeable because the latter lack batch activity standardisation and are not released against pharmacopoeial impurity limits. Food-grade lysozyme declared as additive E 1105 is suitable for food preservation but does not provide veterinary drug master file documentation, viral safety data, endotoxin recovery studies, or the stability commitment required for registered veterinary medicinal products. Recombinant lysozyme from microbial fermentation may contain host-cell proteins and endotoxin profiles that differ by strain; the egg-derived veterinary grade has a defined source and a single-band purity profile that simplifies pharmacopoeial identification. The hydrolytic activity of this API should not be confused with acid-hydrolysed egg protein powders intended as nutritional supplements, because the latter are valued for peptide content rather than enzymatic activity and contain no controlled peptidoglycan-hydrolysing titre.

Premix, Granule, and Drinking Water Solution Stability Boundaries

The premix grade is diluted onto lactose or corn cob carriers at 5–50 g/kg active enzyme and incorporated into complete feed at 1–5 kg/t. In a 500 L ribbon mixer, the carrier is charged first, then the premix grade is added and blended for 10 min at 20–30 rpm; addition of the enzyme before the carrier produces protein segregation and assay variability above 10% relative standard deviation. The feed pelleting step is the main thermal hazard: conditioning above 70°C results in activity losses of 10–20% per pass, and post-pelleting liquid application is specified when pellet die temperatures exceed 65°C.

Granules are produced by fluidised-bed spray granulation using maltodextrin as binder at inlet air 60–70°C and product temperature below 40°C; this route improves flow and reduces dust but requires moisture migration evaluation under 40°C/75% RH for 6 months. For drinking water medication, the solution-dedicated API is dissolved at 0.1% w/v in buffered water at pH 4.0–6.0; activity remains above 90% for 48 h at 25°C. Chlorinated municipal water at 2 ppm free chlorine reduces activity by more than 50% within 4 h due to oxidative inactivation of active-site residues; therefore, dechlorination or stabiliser addition is required before administration. Alkaline drinking water above pH 8.0 is not recommended because the enzyme undergoes time-dependent aggregation and partial denaturation; published data for continuous administration over 72 h in this specific matrix is limited.

All grades are stored in sealed aluminium-laminated pouches with desiccant at 2–8°C. Under these conditions, the manufacturer’s shelf-life specification is 24 months; opened containers for oral powder and premix grades are used within 30 days when stored below 25°C and 60% RH. Repeated freeze-thaw cycles of reconstituted injection solution are not permitted because activity loss after 3 cycles exceeds 10%.